REMARKS

The Examiner has required restriction to one of the following inventions under 35 U.S.C. § 121:

Group I. Claims 1-32 and 44, drawn to a method of treating disease with CD2 antagonists, classified in Class 424, subclass 130.1.

Group II. Claims 33-43, drawn to CD2 antagonists, classified in Class 530, subclass 387.1.

The Examiner contends that the inventions of Groups I and II are distinct from each other. In response to the restriction requirement, Applicants hereby elect to prosecute the claims of Group I, claims 1-32 and 44, drawn to a method of treating disease with CD2 antagonists, without prejudice to Applicants' right to pursue the non-elected subject matter in other applications.

Group I is subject to species elections. Applicants are required to elect one specific type of CD2 antagonist, and if an anti-CD2 antibody is elected, Applicants are required to elect a particular type of anti-CD2 antibody selected from the following:

1. "MEDI-507" and "an anti-CD2 antibody with the proviso that said antibody is not MEDI-507," but it has the same properties as MEDI-507, *i.e.*, "binds to an epitope comprising amino acids 18, 55 or 59 of CD2" and/or "does not inhibit or interfere with the interaction between human CD2 and LFA-3" (as recited in claims 3 and 5, respectively); and

2. "an anti-CD2 antibody with the proviso that said antibody is not MEDI-507" (as in claim 2).

In response, Applicants elect an anti-CD2 antibody as the CD2 antagonist, and "MEDI-507" and "an anti-CD2 antibody with the proviso that said antibody is not MEDI-507" but it has the same properties as MEDI-507 as the anti-CD2 antibody.

Furthermore, Applicants are required to elect one specific species from each of A-D:

A) A "disease" from, *e.g.*, the diseases disclosed in the present specification at pp. 1-3 and claim 15, such as "lung cancer" or "breast cancer" or "T-cell prolymphocytic leukemia" or "anaplastic large cell lymphoma";

B) An "administered cancer therapeutic" (see claim 6) from, *e.g.*, those recited in the instant specification at pp. 67-68, *e.g.*, "paclitaxel" or "palladium" or "tamoxifen" or "TRAIL agonists";

C) A "conjugated therapeutic agent or drug" (see claim 7) from, *e.g.*, those recited in claim 21 and 24, "an antibody that binds to a tumor-associated antigen" or "paclitaxel" or from, *e.g.*, the instant specification at pp. 53-57, such as "methotrexate" or "cisplatin"; and

D) A "standard or experimental therapy for a T-cell malignancy" (see claim 26) species from, *e.g.*, those recited in the instant specification at page 68, first paragraph, such as "Campath" or "Mylotarg" or "Bexxar" or "hematopoietic stem cell transplantation."

In response, Applicants elect peripheral T-cell lymphoma as the disease (species A), cyclosphosphamide as the administered cancer therapeutic (species B), auristatin PHE as the conjugated therapeutic agent or drug (species C), and aggressive combination chemotherapy as the standard experimental therapy (species D). Applicants, upon the allowance of a generic claim, will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim pursuant to 37 C.F.R. § 1.141.

The status of the pending claims in view of the elections made herein are presented in the listing of the claims section of this response.

Applicants respectfully request that the remarks be entered and made of record in the present application. The Examiner is invited to contact the undersigned with any questions concerning the foregoing.

Respectfully submitted,

Date: July 21, 2006

Margaret B. Brivanlou 40,922
Margaret B. Brivanlou (Reg. No.)

Jennifer J. Chheda 46,617
Jennifer J. Chheda (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939